Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlycoVaxyn Initiates First Clinical Study With Shigella Vaccine
The objective of this single-blind, first in human study is to evaluate safety, reactogenicity and immunogenicity of the vaccine at two doses, with or without adjuvant, in 40
The objective of this single-blind, first in human study is to evaluate safety, reactogenicity and immunogenicity of the vaccine at two doses, with or without adjuvant, in 40
Over the course of the last four years, AbD Serotec gradually improved success rates year-on-year starting at 80% in 2006 to reach 98% in 2009. This was mainly
In addition to providing the capability to conduct a variety of studies in healthy volunteers, the core focus of the Port Elizabeth unit is on early phase studies
The ORBIT-1 trial will randomize 96 patients, who will receive for four weeks either one of two different once-daily inhaled doses (100 or 150mg ciprofloxacin delivered by inhalation
The contract modification, which is effective February 22, 2010 and extends until December 31, 2012, provides for up to $61m during a ‘base period’ of performance with options
Bruce Morimoto, vice president of drug development at Allon, said the preclinical data has shown AL-309 to be effective in reducing nerve damage and pain in animal models
The company has also reported that the USPTO has issued US Patent No 7666415, covering bispecific antibody constructs incorporating the company’s proprietary histamine-succinyl-glycine (HSG)-binding 679 antibody. Cynthia Sullivan,
However, FDA has added information to the Specific Populations section of the product label under ‘Heart Failure’ stating that in a placebo-controlled trial of 2,128 patients (1,067 with
The study, conducted at Jolimont Hospital in Haine Saint Paul, Belgium, prospectively evaluated MTWA in 73 consecutive patients who met criteria for implantable cardioverter defibrillator implantation for primary
Merck KGaA reported that the cost of sales grew faster than sales due to underutilisation of capacities, mainly in the chemicals business sector. Therefore, the Group gross margin